Effect of praziquantel on impaired renal function in mice with acute infection of Schistosoma japonicum

doi:10.12140/j.issn.1000-7423.2021.02.013

Abstract

Abstract:

Objective To investigate the occurrence and development of renal inflammation in mice with acute infection of Schistosoma japonicum and evaluate the therapeutic effect of praziquantel on the impairment of renal function in the infected mice. Methods Fifty-five female C57BL/6J mice were randomly divided into 5 groups including the health control group (20), health control with praziquantel-treatment group (5), infection group (20), infection with praziquantel-treatment group(5) and praziquantel treatment group (5). Mice in the latter 3 groups were infected with 14 ± 2 cercariae of S. japonicum. Praziquantel treatment was given from the 6th week after infection. In the health control with praziquantel-treatment group and the infection with praziquantel-treatment group, praziquantel was given at a dosage of 300 mg/kg every 12 h for two consecutive weeks, and the praziquantel dosage in the praziquantel treatment group was 250 mg/kg for 3 consecutive days. Five mice in each of the health control group and the infection group were dissected at weeks 1, 3, 6 and 8 after infection. Five mice in each of the health control with praziquantel-treatment group, the infection with praziquantel-treatment group and the praziquantel treatment group were dissected at week 8 after infection. Urine and blood samples were collected to detect the levels of urinary protein and serum creatinine to evaluate renal function of the mice. The histopathological changes of kidney in each group were observed by HE staining. The infiltration of macrophages in the kidneys of mice was assessed by F4/80 immunohistochemical staining. Quantitative real-time PCR (qRT-PCR) and Western blotting were used to detect the relative transcription and protein expression level of mRNA of inflammatory cytokines (TNF-α, TGF-β, IL-1β and IL-6) and macrophage chemokine CCL2. Results At weeks 1, 3, 6 and 8 after infection, the urine protein contents in the infection group were (1.67 ± 0.52) g/L, (2.17 ± 0.41) g/L, (3.00 ± 0.89) g/L and (4.00 ± 0. 63) g/L, respectively, all higher than those in the health control group (P < 0.01). The serum creatinine levels in the infection group were (10.01 ± 1.45)μmol/, (13.00 ± 2.12)μmol/, (14.33 ± 1.21) and (19.00 ± 2.54) μmol/L, which were higher than those in the health control group (P > 0.05 or P < 0.01). qRT-PCR results showed that in the infection group the relative transcription level of inflammatory factor TNF-α mRNA were 2.47 ± 0.51, 3.14 ± 1.43, 1.83 ± 0.31 and 7.48 ± 5.54, the relative transcription level of TGF-β mRNA were 0.94 ± 0.24, 2.80 ± 1.07, 2.72 ± 0.88 and 3.03 ± 0.36, the relative transcription level of IL-1β mRNA were 1.49 ± 0.28, 4.32 ± 1.85, 2.08 ± 0.69 and 2.81 ± 0.73, the relative transcription level of IL-6 mRNA were 1.96 ± 0.31, 1.48 ± 0.35, 2.38 ± 1.17 and 2.85 ± 1.32, respectively, which were all higher in the health control group (P < 0.05 or P < 0.01). Western blotting analysis showed that the expression of TNF-α and IL-1β in the infection group were higher than those in the health control group. The relative transcription level of macrophage chemokine CCL2 mRNA in the infection group were 1.84 ± 0.17, 3.42 ± 0.85, 3.03 ± 1.00 and 2.63 ± 0.43, respectively, which were also higher than that in the health control group (P < 0.01). HE staining of renal pathological sections showed massive inflammatory cell infiltration, glomerular enlargement, and mesangial cell proliferation. Immunohistochemical results showed that the F4/80-positive areas in the kidneys of the infection group were (1.99 ± 0.49)%, (4.27 ± 0.90)%, (6.71 ± 1.38)% and (9.83 ± 1.91)%, which were higher than those in the health control group (P < 0.01). After treatment with praziquantel for two weeks, the renal tissue impairment and glomerular mesangial cell proliferation were alleviated. Compared with the infection group, the urinary protein content [(2.67 ± 0.52) g/L], serum creatinine level [(14.17 ± 2.88) μmol/L], F4/80-positive area [(5.92 ± 1.81)%], mRNA relative transcription of TGF-β and IL-6 (0.99 ± 0.23, 1.24 ± 0.53), and the protein levels of TNF-α and IL-1β were decreased in the infection with praziquantel-treatment group (P < 0.05 or P < 0.01), but did not change significantly in the praziquantel treatment group (P > 0.05). Compared with the infection group (5.29 ± 2.98, 2.81 ± 0.73, 2.63 ± 0.43), the mRNA relative transcription of TNF-α, IL-1β and CCL2 were decreased (P < 0.05 or P < 0.01) in the infection with praziquantel-treatment group (0.98 ± 0.36, 0.95 ± 0.33, 0.80 ± 0.27) and the praziquantel treatment group (1.56 ± 0.66, 1.76 ± 0.76, 1.41 ± 0.48). Conclusion In mice infected with S. japonicum, renal inflammation may occur in the early and acute stages of infection, accompanied by infiltration of macrophages in renal tissues, and impairment in glomerular and renal functions. Treatment with praziquantel for two weeks can significantly ameliorate renal inflammation and renal function in mice infected with S. japonicum.

Key words: Schistosoma japonicum, Kidney injury, Inflammation, Praziquantel, Macrophages

CLC Number:

R532.21

ZHAO Cheng-si, QIN Min, TAN Ming-juan, MIAO Ting-ting, SHAO Tian-ye, LIU Xin-jian, WANG Yong. Effect of praziquantel on impaired renal function in mice with acute infection of Schistosoma japonicum[J]. CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES, 2021, 39(2): 200-209.

Figures/Tables 7

Fig. 1

Fig. 2

Fig. 3

Fig. 4

Fig. 5

Fig. 6

Fig. 7

References 38

[1]	Yang JR, Xu MX, Tan XD. Healthy China Strategy and schistosomiasis control[J]. Chin J Schisto Control, 2020,32(4):419-422. (in Chinese)
[1]	( 杨晋如, 徐明星, 谭晓东. 健康中国战略与血吸虫病防控[J]. 中国血吸虫病防治杂志, 2020,32(4):419-422.)
[2]	Guan Z, Lu S, Li SZ, et al. Epidemic status and prevention and control challenges of schistosomiasis among floating population in China[J]. Chin J Parasitol Parasit Dis, 2017,35(6):598-603. (in Chinese)
[2]	( 关周, 吕山, 李石柱, 等. 我国流动人口血吸虫病流行现状及防控挑战[J]. 中国寄生虫学与寄生虫病杂志, 2017,35(6):598-603.)
[3]	Andersson KL, Chung RT. Hepatic schistosomiasis[J]. Curr Treat Options Gastroenterol, 2007,10(6):504-512.
[4]	Sun YJ, Li ZQ, Lu FL. Research progress on immunopathological mechanism of egg granuloma of Schistosoma japonicum[J]. Chin J Parasitol Parasit Dis, 2019,37(6):97-101, 106. (in Chinese)
[4]	( 孙钰浚, 李钊琪, 吕芳丽. 日本血吸虫虫卵肉芽肿免疫病理机制研究进展[J]. 中国寄生虫学与寄生虫病杂志, 2019,37(6):97-101, 106.)
[5]	Gryseels B. Schistosomiasis[J]. Infect Dis Clin N Am, 2012,26(2):383-397.
[6]	Andrade ZA, Queiroz ACD. Renal lesions in hepatosplenic schistosomiasis[J]. Rev Inst Med Trop S?o Paulo, 1968,10(1):36-40.
[7]	Colley DG, Secor WE. Immunology of human schistosomiasis[J]. Parasite Immunol, 2014,36(8):347-357.
[8]	Neves PDMM, Bezerra KS, Silveira MAD, et al. Schistosoma mansoni and membranous nephropathy[J]. Kidney Int, 2016,89(4):959-959.
[9]	Neves PDMDM, Jorge LB, Cavalcante LB, et al. Schistosomiasis-associated glomerulopathy: Clinical aspects, pathological characteristics, and renal outcomes[J]. Clin nephrol, 2020,93(5):251-261.
[10]	Fabiana, Oliveira, Goncalves, et al. Schistosoma mansoni associated glomerulopathy with IgA mesangial deposits: case report[J]. J Brasileira De Nefrologia, 2017,39(1):86-90.
[11]	Rodrigues VL, Otoni A, Voieta I, et al. Glomerulonephritis in schistosomiasis mansoni: a time to reappraise[J]. Rev Soc Bras Med Trop, 2010,43(6):638-642.
[12]	Burke ML, Jones MK, Gobert GN, et al. Immunopathogenesis of human schistosomiasis[J]. Parasite Immunol, 2009,31(4):163-176.
[13]	Abensur H, Nussenzveig I, Saldanha LB, et al. Nephrotic syndrome associated with hepatointestinal schistosomiasis[J]. Rev Inst Med Trop S?o Paulo, 1992,34(4):273-276.
[14]	Sobh MA, Moustafa FE, Sally SM, et al. Characterisation of kidney lesions in early schistosomal-specific nephropathy[J]. Nephrol Dial Transplant, 1988,3(4):392-398.
[15]	Yan ZZ, Hochman A, Zhou ZY, et al. Immune complex nephropathy of Schistosoma japonicum[J]. Chin J Parasitol Parasit Dis, 1986,4(1):14-17. (in Chinese)
[15]	( 严自助, Hochman A, 周中源, 等. 日本血吸虫免疫复合物肾病的实验研究[J]. 中国寄生虫学与寄生虫病杂志, 1986,4(1):14-17.)
[16]	Chisty MM, Nargis M, Sato H, et al. Schistosoma mansoni: kinetics of glomerulonephritis in Mongolian gerbils and its correlation with intensity and duration of infection[J]. Parasite Paris France, 2002,9(2):143-151.
[17]	Sobh M, Moustafa F, Hamid S, et al. Schistosomal-specific nephropathy in Syrian golden hamsters: treatment by induction of antigen excess[J]. Nephrol Dial Transplant, 1996,11(11):2178-2184.
[18]	Xu DW, Bao XQ, Wang YZ, et al. Study on immune response of Schistosoma japonicum nephropathy[J]. Chin J Schisto Control, 1989,1(2):47-50. (in Chinese)
[18]	( 须大卫, 包献清, 王雅珍, 等. 日本血吸虫肾病免疫反应的研究[J]. 中国血吸虫病防治杂志, 1989,1(2):47-50.)
[19]	Donate-Correa Luis-Rodríguez Martín-Núez, et al. Inflammatory targets in diabetic nephropathy[J]. J Clin Med, 2020,9(2):458-470.
[20]	Meng XM. Inflammatory Mediators and Renal Fibrosis[J]. Adv Exp Med Biol, 2019,1165:381-406.
[21]	Meng XM, Nikolic-Paterson DJ, Lan HY. Inflammatory processes in renal fibrosis[J]. Nat Rev Nephrol, 2014,10(9):493-503.
[22]	Chung ACK, Lan HY. Chemokines in renal injury[J]. J Am Soc Nephrol, 2011,22(5):802-809.
[23]	Lee SB, Kalluri R. Mechanistic connection between inflammation and fibrosis[J]. Kidney Int, 2010,78(Suppl 119):S22-26.
[24]	Liu YH. Cellular and molecular mechanisms of renal fibrosis[J]. Nat Revs Nephrol, 2011,7(12):684-696.
[25]	Boor P, Ostendorf T, Floege J. Renal fibrosis: novel insights into mechanisms and therapeutic targets[J]. Nat Rev Nephrol, 2010,6(11):643-656.
[26]	Watkins BM. Drugs for the control of parasitic diseases: current status and development in schistosomiasis[J]. Trends Parasitol, 2003,19(11):477-478.
[27]	Wang W, Zhao CS, Miu TT, et al. Inhibitory effect of praziquanl on proliferation and inflammatory response of spleen macrophages in mice infected with Schistosoma japonicum[J]. Chin J Parasitol Parasit Dis, 2020,38(3):263-270. (in Chinese)
[27]	( 王伟, 赵成思, 缪婷婷, 等. 吡喹酮治疗对日本血吸虫感染小鼠脾巨噬细胞增殖和炎症反应的抑制作用[J]. 中国寄生虫学与寄生虫病杂志, 2020,38(3):263-270.)
[28]	Liang YJ, Jie L, Quan Y, et al. New insight into the antifibrotic effects of praziquantel on mice in infection with Schistosoma japonicum[J]. PLoS One, 2011,6(5):e20247.
[29]	Liu J, Kong D, Qiu J, et al. Praziquantel ameliorates CCl4-induced liver fibrosis in mice by inhibiting TGF-β/Smad signalling via upregulating Smad7 in hepatic stellate cells[J]. Br J Pharmacol, 2019,176(24):4666-4680.
[30]	Barsoum R. The changing face of schistosomal glomerulopathy[J]. Kidney Int, 2005,66(6):2472-2484.
[31]	Hillyer GV, Lewert RM. Studies on renal pathology in hamsters infected with Schistosoma mansoni and S. japonicum[J]. Am J Trop Med Hyg, 1974,23(3):404-411.
[32]	Bezerra D, Duarte, Alexandre L, et al. Acute kidney injury in schistosomiasis: a retrospective cohort of 60 patients in Brazil[J]. J Parasitol, 2015,101(2):244-247.
[33]	Kano K, Milgrom KF. Immune complex disease[J]. Vox Sang, 1980,38(3):121-137.
[34]	Gong FL. Medical immunology[M]. 3rd ed. Beijing: Science Press, 2009: 227-228. (in Chinese)
[34]	( 龚非力. 医学免疫学[M]. 3版. 北京: 科学出版社, 2009: 227-228.)
[35]	Balow JE, Cho ME, Austin HA. Immunologic renal diseases[M]. Philadelphia: Lippincott Williams & Wilkins, 2008: 462.
[36]	Anders HJ, Ryu M. Renal microenvironments and macrophage phenotypes determine progression or resolution of renal inflammation and fibrosis[J]. Kidney Int, 2011,80(9):915-925.
[37]	Eardley KS, Kubal C, Zehnder D, et al. The role of capillary density, macrophage infiltration and interstitial scarring in the pathogenesis of human chronic kidney disease[J]. Kidney Int, 2008,74(4):495-504.
[38]	Nishida M, Hamaoka K. Macrophage phenotype and renal fibrosis in obstructive nephropathy[J]. Nephron Expl Nephrol, 2008,110(1):e31-36.